Table 2.
Patient characteristics a
| Offered incentive ( N = 481) | Not offered incentive ( N = 534) | |
|---|---|---|
| Age (mean, SD) | 66.2 (10.2) | 66.3 (9.6) |
| Sex | ||
| Male | 281 (58.4) | 308 (57.7) |
| Female | 162 (33.7) | 182 (34.1) |
| Unknown | 38 (7.9) | 44 (8.2) |
| SIMD deprivation categoryb | ||
| 1–3 (least deprived) | 138 (28.7) | 134 (25.1) |
| 4–7 | 242 (50.3) | 274 (51.4) |
| 8–10 (most deprived) | 101 (21.0) | 125 (23.5) |
| Geographic areasb | ||
| Angus and Dundee | 217 (45.1) | 215 (40.3) |
| Fife | 200 (41.6) | 234 (43.9) |
| Perth | 64 (13.3) | 84 (15.8) |
| Target patient group | ||
| FAST | 158 (32.9) | 174 (32.6) |
| SCOT | 84 (17.5) | 97 (18.2) |
| PATHWAY 1 | 46 (9.6) | 47 (8.8) |
| PATHWAY 2 | 101 (21.0) | 109 (20.4) |
| PATHWAY 3 | 92 (19.1) | 107 (20.0) |
aFAST, Febuxostat versus Allopurinol Streamlined Trial; PATHWAY, Prevention and Treatment of Hypertension with Algorithm Guided Therapy, British Heart Foundation–funded trials; SCOT, Standard care versus Celecoxib Outcome Trial; SIMD, SD, Standard deviation; Scottish Index of Multiple Deprivation. Data are mean (SD) or number (%). There were no significant differences between groups bIncludes one patient with missing data.